Frowiss ®

Albert B. Frowiss, Sr.
EEOICPA Independent Claims Advocate

 

Albert B. Frowiss, Sr.

EEOICPA Independent Claims Advocate

P.O. Box 909

Rancho Santa Fe, CA 92067

Phone or Fax: 858.756.1494

Email: frowiss@frowiss.org

 

Special Exposure Cohort (SEC) Cancers


 

(1)  Leukemia, if onset of the disease occurred at least two years after first exposure.

(2)  Primary or secondary* lung cancer, including bronchi and trachea, sarcoma of the lung (other than in situ lung cancer that is discovered during or after a post-mortem exam).  Does not include mesothelioma or pleura cancer.

(3)  Primary or secondary* bone cancer (including the bone form of solitary plasmacytoma, myelodysplastic syndrome, myelofibrosis with myeloid metaplasia, essential thrombocytosis or essential thrombocythemia, primary polycythemia vera [also called polycythemia rubra vera, P. vera, primary polycythemia, proliferative polycythemia, spent-phase polycythemia, or primary erythremia].

(4)  Primary or secondary* renal (kidney) cancer

(5)  The following diseases, provided onset was at least five years after the first exposure:

(i)     Multiple myeloma;

(ii)    Lymphomas (other than Hodgkin’s disease); includes Waldenstrom's   macroglobulinemia and mycosis fungoides.

(iii)   Primary cancer of the:

(A)    thyroid

(B)    male or female breast

(C)    esophagus

(D)    stomach

(E)    pharynx, including all three areas, oropharynx, nasopharynx and hypopharynx.  The oropharynx, e.g., includes base of tongue, soft palate and tonsils.  The hypopharynx includes the pyriform sinus.

(F)    small intestine

(G)    pancreas

(H)    bile ducts, including ampulla of vater

(I)     gall bladder

(J)     salivary gland

(K)    urinary bladder

(L)    brain (malignancies only, not including intracranial endocrine glands and other parts of the central nervous system or borderline astrocytomas)

(M)    colon, including rectum and appendix

(N)    ovary

(O)    liver (except if cirrhosis or hepatitis B is indicated)

Other malignant cancers (Prostate, Skin Cancer, etc.) may be compensable.  Prostate Cancer with metastasis ("W/METS") or multiple occurrences of skin cancer(s) require further evaluation.

* Secondary cancers are typically diagnosed as having been caused by metastasis (spread) from primary cancers.